ClearPoint Neuro annual operating margin
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
ClearPoint Neuro's operating margin was −65.36% for fiscal 2025.
View full ClearPoint Neuro company overview| Fiscal year | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −65.36% | −2.49 pp |
| 2024 | 2024-12-31 | −62.87% | +30.83 pp |
| 2023 | 2023-12-31 | −93.70% | −14.23 pp |
| 2022 | 2022-12-31 | −79.47% | +2.58 pp |
| 2021 | 2021-12-31 | −82.05% | −33.57 pp |
| 2020 | 2020-12-31 | −48.48% | −7.53 pp |
| 2019 | 2019-12-31 | −40.96% | +30.41 pp |
| 2018 | 2018-12-31 | −71.37% | +14.49 pp |
| 2017 | 2017-12-31 | −85.86% | +44.39 pp |
| 2016 | 2016-12-31 | −130.25% | +65.08 pp |
| 2015 | 2015-12-31 | −195.34% | −47.72 pp |
| 2014 | 2014-12-31 | −147.61% | +42.56 pp |
| 2013 | 2013-12-31 | −190.17% | −128.30 pp |
| 2012 | 2012-12-31 | −61.87% | +93.22 pp |
| 2011 | 2011-12-31 | −155.09% | +201.36 pp |
| 2010 | 2010-12-31 | −356.45% | — |
| Fiscal quarter | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −94.15% | −32.52 pp |
| Q1 2026 | 2026-03-31 | −69.90% | +2.73 pp |
| Q4 2025 | 2025-12-31 | −67.68% | +4.85 pp |
| Q3 2025 | 2025-09-30 | −59.54% | +3.96 pp |
| Q2 2025 | 2025-06-30 | −61.64% | −1.52 pp |
| Q1 2025 | 2025-03-31 | −72.63% | −17.44 pp |
| Q4 2024 | 2024-12-31 | −72.53% | −3.42 pp |
| Q3 2024 | 2024-09-30 | −63.51% | +21.48 pp |
| Q2 2024 | 2024-06-30 | −60.12% | +59.73 pp |
| Q1 2024 | 2024-03-31 | −55.19% | +49.94 pp |
| Q4 2023 | 2023-12-31 | −69.10% | +17.27 pp |
| Q3 2023 | 2023-09-30 | −84.99% | −11.24 pp |
| Q2 2023 | 2023-06-30 | −119.85% | −39.00 pp |
| Q1 2023 | 2023-03-31 | −105.14% | −28.33 pp |
| Q4 2022 | 2022-12-31 | −86.37% | +6.62 pp |
| Q3 2022 | 2022-09-30 | −73.75% | +9.42 pp |
| Q2 2022 | 2022-06-30 | −80.85% | +18.98 pp |
| Q1 2022 | 2022-03-31 | −76.80% | −22.68 pp |
| Q4 2021 | 2021-12-31 | −92.99% | −32.07 pp |
| Q3 2021 | 2021-09-30 | −83.17% | −47.02 pp |
| Q2 2021 | 2021-06-30 | −99.82% | −40.30 pp |
| Q1 2021 | 2021-03-31 | −54.12% | −15.32 pp |
| Q4 2020 | 2020-12-31 | −60.93% | −16.75 pp |
| Q3 2020 | 2020-09-30 | −36.15% | −5.04 pp |
| Q2 2020 | 2020-06-30 | −59.52% | −9.91 pp |
| Q1 2020 | 2020-03-31 | −38.80% | +0.52 pp |
| Q4 2019 | 2019-12-31 | −44.17% | −1.19 pp |
| Q3 2019 | 2019-09-30 | −31.10% | +35.65 pp |
| Q2 2019 | 2019-06-30 | −49.61% | +49.76 pp |
| Q1 2019 | 2019-03-31 | −39.32% | +48.59 pp |
| Q4 2018 | 2018-12-31 | −42.98% | +66.14 pp |
| Q3 2018 | 2018-09-30 | −66.75% | +10.55 pp |
| Q2 2018 | 2018-06-30 | −99.37% | −7.15 pp |
| Q1 2018 | 2018-03-31 | −87.91% | −20.47 pp |
| Q4 2017 | 2017-12-31 | −109.12% | +0.37 pp |
| Q3 2017 | 2017-09-30 | −77.30% | +28.46 pp |
| Q2 2017 | 2017-06-30 | −92.22% | +93.95 pp |
| Q1 2017 | 2017-03-31 | −67.44% | +71.27 pp |
| Q4 2016 | 2016-12-31 | −109.49% | −15.57 pp |
| Q3 2016 | 2016-09-30 | −105.77% | +48.84 pp |
| Q2 2016 | 2016-06-30 | −186.17% | +138.70 pp |
| Q1 2016 | 2016-03-31 | −138.71% | +152.73 pp |
| Q4 2015 | 2015-12-31 | −93.92% | +185.16 pp |
| Q3 2015 | 2015-09-30 | −154.60% | +258.90 pp |
| Q2 2015 | 2015-06-30 | −324.87% | −138.51 pp |
| Q1 2015 | 2015-03-31 | −291.45% | −557.94 pp |
| Q4 2014 | 2014-12-31 | −279.08% | −103.28 pp |
| Q3 2014 | 2014-09-30 | −413.50% | −212.82 pp |
| Q2 2014 | 2014-06-30 | −186.36% | +200.90 pp |
| Q1 2014 | 2014-03-31 | 266.50% | +374.63 pp |
| Q4 2013 | 2013-12-31 | −175.81% | −149.97 pp |
| Q3 2013 | 2013-09-30 | −200.68% | −110.82 pp |
| Q2 2013 | 2013-06-30 | −387.26% | −343.01 pp |
| Q1 2013 | 2013-03-31 | −108.13% | +9.36 pp |
| Q4 2012 | 2012-12-31 | −25.84% | +86.81 pp |
| Q3 2012 | 2012-09-30 | −89.86% | +34.02 pp |
| Q2 2012 | 2012-06-30 | −44.25% | +159.39 pp |
| Q1 2012 | 2012-03-31 | −117.49% | +102.48 pp |
| Q4 2011 | 2011-12-31 | −112.65% | — |
| Q3 2011 | 2011-09-30 | −123.88% | — |
| Q2 2011 | 2011-06-30 | −203.63% | — |
| Q1 2011 | 2011-03-31 | −219.97% | — |
Over the last five reported fiscal years, ClearPoint Neuro's operating margin decreased from −48.48% to −65.36%, a change of −16.88 percentage points. The latest reported quarter, Q2 2026, shows −94.15%.
Operating margin measures the percentage of revenue left after operating costs and expenses. It shows how much operating profit a company generates from each dollar of revenue.
TickerStat calculates operating margin as SEC-reported operating income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review ClearPoint Neuro filings at SEC.gov ↗